Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIRILON vs TESTRED
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men, libido enhancement in women (limited use)
Testosterone replacement therapy for male hypogonadism,Delayed puberty in males,Metastatic breast cancer in women (limited use)
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
No dose adjustment required for renal impairment. Use with caution in patients with nephrotic syndrome due to potential fluid retention.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment due to potential fluid retention.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose to 100 mg every 2 weeks and monitor liver function.
WARNING: Use in men with breast cancer or known/suspected prostate cancer is contraindicated. Risk of accelerated growth of prostate cancer and exacerbation of breast cancer.
Testosterone esters (e.g., testosterone cypionate, testosterone enanthate) are contraindicated in pregnancy. Androgens can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities, especially during the first trimester when genital differentiation occurs. Risk is dose-dependent and increases with higher maternal androgen levels. No adequate human studies; animal studies show teratogenic effects at high doses.
Pregnancy Category X. Testosterone can cause virilization of female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities. Risk is highest during first trimester when organogenesis occurs. Contraindicated in pregnancy.
VIRILON (methyltestosterone) is an androgen used for testosterone replacement therapy. Monitor liver function tests due to risk of hepatotoxicity. Avoid in patients with prostate or breast cancer. May cause priapism, gynecomastia, and edema. Use with caution in elderly due to increased risk of prostatic hyperplasia.
Monitor for signs of virilization in women and precocious puberty in children. Measure serum testosterone levels periodically to ensure therapeutic range and avoid supraphysiologic levels. Assess liver function tests, lipid profile, and hematocrit/hemoglobin at baseline and periodically. Use with caution in patients with known or suspected prostate cancer or breast cancer. Avoid in men with severe lower urinary tract symptoms due to benign prostatic hyperplasia. Intramuscular injections should be given deep into the gluteal muscle to minimize injection site reactions.
No interactions on record
No interactions on record
VIRILON and TESTRED are distinct pharmacological agents. VIRILON belongs to the Androgen class and is primarily used for Male hypogonadism (primary and hypogonadotropic)Delayed puberty in malesOff-label: Androgen replacement in transgender men, libido enhancement in women (limited use). TESTRED belongs to the Androgen class and is primarily used for Testosterone replacement therapy for male hypogonadismDelayed puberty in malesMetastatic breast cancer in women (limited use). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VIRILON carries a safety status of Category C, whereas TESTRED safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP3A4 and other CYP450 enzymes; metabolites are excreted in urine.
Hepatic via CYP3A4 and other CYP enzymes; metabolites include androsterone and etiocholanolone.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Approximately 95% bound to plasma proteins, primarily sex hormone-binding globulin (SHBG) and albumin.
Approximately 98-99% bound to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%) in adult males. Free testosterone fraction is ~1-2%.
Apparent volume of distribution is approximately 0.5–1.0 L/kg, indicating distribution into total body water with some tissue binding.
Volume of distribution for testosterone is approximately 0.5-1.0 L/kg, indicating distribution into total body water and tissues (e.g., muscle, prostate). Clinical meaning: wide distribution, tissue binding important for effects.
Oral bioavailability is approximately 40–60% due to extensive first-pass metabolism in the liver. Sublingual administration may achieve higher systemic exposure.
Oral testosterone: low and variable (<10%) due to extensive first-pass metabolism; methyltestosterone: ~40-60% (resistant to hepatic metabolism). Intramuscular (enanthate): 100% (systemic). Transdermal: ~10-14% (patch), 6-12% (gel). Buccal: ~80-90%.
Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment provided.
Not recommended for use in pediatric patients. Safety and efficacy have not been established; may cause premature epiphyseal closure and virilization.
Not recommended for use in children; safety and efficacy not established.
Use with caution in elderly patients due to increased risk of prostatic hypertrophy and prostatic carcinoma. Monitor prostate-specific antigen (PSA) regularly. Consider lower starting dose of 100 mg every 2 weeks.
Use with caution in elderly patients due to increased risk of prostatic hypertrophy and cardiovascular events; monitor prostate-specific antigen and hematocrit regularly.
WARNING: VIRILIZATION IN WOMEN, PRECOCIOUS PUBERTY IN CHILDREN, AND HEPATOTOXICITY. Testosterone has been associated with hepatic adenomas and hepatocellular carcinoma.
Monitor for polycythemia, sleep apnea, cardiovascular risk, hypercalcemia in breast cancer patients, and potential for secondary exposure (virilization in children).
Known or suspected prostate cancer, male breast cancer, severe hepatic impairment, pregnancy, lactation.
Take with food to reduce GI upset. Avoid grapefruit juice as it may increase methyltestosterone levels. Alcohol consumption may exacerbate hepatotoxicity.
No significant food interactions. Avoid excessive alcohol consumption as it may increase risk of hepatotoxicity. Grapefruit juice does not interact significantly. Maintain a balanced diet to support overall health during androgen therapy.
Testosterone is excreted into breast milk in small amounts; M/P ratio is not established. Use in nursing mothers is not recommended due to potential adverse effects on the infant, including virilization and disruption of hormonal balance. Alternative therapies should be considered if breastfeeding is desired.
Testosterone is excreted into breast milk. M/P ratio not established. Potential adverse effects include virilization in female infants and growth acceleration. Use during breastfeeding is contraindicated.
Not applicable; use during pregnancy is contraindicated. No dose adjustment studies exist. If inadvertent use occurs, discontinue immediately and monitor for fetal effects. Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, altered metabolism) would likely require dose adjustments if use were considered, but due to teratogenicity, no safe dosing regimen can be recommended.
No dose adjustments applicable as Testosterone is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy include increased volume of distribution and altered protein binding, but use is not recommended.
Take exactly as prescribed; do not increase dose or frequency.,Report symptoms of priapism (prolonged erection), jaundice, or edema immediately.,Regular blood tests (liver function, PSA, lipid profile) are required.,Avoid alcohol as it may increase risk of liver damage.,Women of childbearing age should use effective contraception due to potential virilization of fetus.,Do not use if you have a history of prostate or breast cancer.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,Report any signs of virilization (e.g., deepened voice, facial hair growth, acne) or unusual changes in mood, sleep, or libido.,For transdermal formulations, apply to clean, dry skin on the back, abdomen, or thighs; rotate sites to avoid irritation.,Do not use in women who are or may become pregnant; can cause harm to the fetus.,Keep out of reach of children; store at room temperature away from moisture and heat.,Inform your doctor of all other medications, including over-the-counter, vitamins, and herbal supplements.,Regular blood tests are required to monitor safety and effectiveness.